ArticleFrontiers in immunology2026
Efficacy and safety of Telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: insights from a real-world study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of telitacicept in IgA vasculitis nephritis: a single-center retrospective study.European journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In this study, we evaluated the efficacy and safety of Telitacicept for treating patients with primary IgA nephropathy (IgAN) in our single hospital. We also explored the effect of Telitacicept on urinary Gd-IgA1 levels among patients with IgAN. Methods: A retrospective study was conducted. Patients were grouped according to 24-hour proteinuria (≥ 2.0 vs. < 2.0 g/day), eGFR (≥ 35 vs. < 35 mL/min/1.73 m Results: A total of 68 IgAN patients who received Telitacicept were included in this study. At baseline, the median baseline proteinuria was 1753.5 mg/day, and eGFR was 71.5 ml/min/1.73m². Significant reductions in proteinuria were observed at 1 month and sustained through 6 months of follow-up. The eGFR remained stable throughout the follow-up period. Subgroup analyses stratified by baseline proteinuria, eGFR, gender, age, and therapy options showed no significant differences in proteinuria reduction rates. Both patients initially starting Telitacicept and those who had previously failed other therapy before starting it showed significant reductions in proteinuria and stable eGFR. Importantly, we observed an improvement in the eGFR slope within the Prior Treatment plus Telitacicept Group, with the annual rate of decline slowing from 6.35 ml/min/1.73m²/year pre-treatment to 3.68 ml/min/1.73m²/year after Telitacicept therapy. Furthermore, the responsive group to Telitacicept exhibited significantly higher IgA levels compared to the non-responsive group. Compared with patients receiving supportive care alone, those who initially added Telitacicept showed a greater reduction in proteinuria by the last follow-up. Additionally, Telitacicept therapy led to a decrease in urinary Gd-IgA1/Cr levels. Telitacicept treatment was well-tolerated. Conclusions: In IgAN, Telitacicept demonstrated promising efficacy, significantly reducing proteinuria and stabilizing eGFR, with a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.